Trial · NCT04276727
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Reduction in CIPN symptoms | 6 weeks | A clinically significant reduction in pain (at least a 30% decrease in total BPI SF score as relates to the index neuropathic pain) between baseline and 6 weeks. |
| Secondary | Treatment effect on Chemotherapy Induced Peripheral Neuropathy | 6 weeks | Changes in EORTC QLQ (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires) CIPN-20 (severity of 20 symptoms rated on 4 point scale from Not at all to Very much) |
| Secondary | Treatment effect on quality of life functions | 6 weeks | Changes in EORTC QLC-c30 scores (30 symptoms on same scale as CIPN) |
| Secondary | Treatment effect on pain scores | 6 weeks | Changes in Brief Pain Inventory - Short Form scores (13 symptoms rated from 0 None to 10 Worst) |
| Secondary | Treatment effect on anxiety and depression | 6 weeks (14 symptoms rated from 0 to 3 in severity) | Changes in Hospital Anxiety and Depression Scale (HADS) scores |
| Secondary | Treatment effect on pain catastrophisation | 6 weeks (13 questions rated from 0-4 in severity) | Changes in Pain Catastrophising Scale (PCS) scores |
| Secondary | Treatment effect on side effects | 6 weeks | Changes in side effects (Yes/No to any SEs, description of SE to be given) |
| Secondary | Treatment effect on physical activity | 6 weeks | Changes in Actigraph data (measures of step counts, amount of moderate/vigorous activity and sleep times/efficiency) |
| Secondary | Perceived effects of IMP | 6 weeks | Changes in perceived effects questions (How long participant thinks treatment takes to take effect and how long it lasts for) |
| Other | Changes in Functional Magnetic Imaging data | 6 weeks | Changes in FMRI data pre and post treatment |
| Other | Post treatment changes in CIPN | 12 weeks (from baseline) | Changes in CIPN-20 scores (see secondary outcomes above for details of all questionnaire measures) |
| Other | Post treatment changes in quality of life measures | 12 weeks (from baseline) | Changes in QLQ-c30 |
| Other | Post treatment changes in pain scores | 12 weeks (from baseline) | Changes in BPI-SF |
| Other | Post treatment changes in anxiety and depression | 12 weeks (from baseline) | Changes in HADS scores |
| Other | Post treatment changes in pain catastrophising | 12 weeks (from baseline) | Changes in PCS |
| Other | Post treatment changes in side effects | 12 weeks (from baseline) | Changes in Side effects |
| Other | Post treatment changes in physical activity | 12 weeks (from baseline) | Changes in Actigraph data |
| Other | Changes in sensory measures | 6 weeks and 12 weeks (from baseline) | Changes in QST data |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04276727/registered